Egetis Therapeutics AB (publ) (STO:EGTX)

Sweden flag Sweden · Delayed Price · Currency is SEK
5.20
-0.22 (-4.06%)
Aug 22, 2025, 5:29 PM CET
-4.06%
Market Cap1.87B
Revenue (ttm)47.30M
Net Income (ttm)-337.20M
Shares Out359.24M
EPS (ttm)-0.94
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,128,368
Average Volume613,267
Open5.34
Previous Close5.42
Day's Range5.00 - 5.35
52-Week Range3.03 - 7.67
Beta1.07
RSI44.67
Earnings DateAug 21, 2025

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 40
Stock Exchange Nasdaq Stockholm
Ticker Symbol EGTX
Full Company Profile

Financial Performance

In 2024, Egetis Therapeutics AB's revenue was 46.10 million, a decrease of -19.97% compared to the previous year's 57.60 million. Losses were -343.60 million, 5.11% more than in 2023.

Financial Statements

News

There is no news available yet.